Inhaled Drug Delivery for Tuberculosis Therapy

By Muttil Pavan   Wang Chenchen   Hickey Anthony  

Pharmaceutical Research, Vol. 26, Iss. 11, 2009-11 ,pp. : 2401-2416

Springer Publishing Company

Access to resources Recommend Favorite

PA-824, moxifloxacin and pyrazinamide combination therapy for tuberculosis

By Dawson Rodney   Diacon Andreas  

Expert Opinion on Investigational Drugs, Vol. 22, Iss. 7, 2013-11 ,pp. : 927-932

Informa Healthcare

Access to resources Recommend Favorite

Warning: anti-TNF therapy might cause tuberculosis

By O'Neill L.  

Trends in Pharmacological Sciences, Vol. 23, Iss. 1, 2002-01 ,pp. : 9-9

Elsevier

Access to resources Recommend Favorite

Tuberculosis susceptibility – implications for drug development and therapy

By Snell Noel J C  

Expert Opinion on Pharmacotherapy, Vol. 4, Iss. 9, 2003-09 ,pp. : 1455-1460

Informa Healthcare

Access to resources Recommend Favorite

Host-directed therapy of tuberculosis: what is in it for microRNA?

By Iannaccone Marco   Dorhoi Anca   Kaufmann Stefan HE  

Expert Opinion on Therapeutic Targets, Vol. 18, Iss. 5, 2014-05 ,pp. : 491-494

Informa Healthcare

Access to resources Recommend Favorite